Multi-Center,Open-Label,Randomized,Phase 1B Study Evaluating Safety and Tolerability of Intravenous recombinant human mannose-binding lectin (rhMBL) in Pts With Multiple Myeloma Receiving Melphalan-Based High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplant.

Trial Profile

Multi-Center,Open-Label,Randomized,Phase 1B Study Evaluating Safety and Tolerability of Intravenous recombinant human mannose-binding lectin (rhMBL) in Pts With Multiple Myeloma Receiving Melphalan-Based High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplant.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2011

At a glance

  • Drugs Mannose binding lectin (Primary) ; Antineoplastics; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Oct 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 27 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Feb 2009 Planned end date (Feb 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top